Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 10/20 | 0.60 |
| ▸ | GIPR | P48546 | 10/20 | 0.60 |
| ▸ | PTGES | O14684 | 2/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5585461 | 0.93 | GCGR (0.56) | GCGRGIPRPTGESALOX5MEN1 | |
| SCHEMBL5585426 | 0.91 | GCGR (0.55) | GCGRGIPRMEN1KMT2AKDM4E | |
| SCHEMBL5585380 | 0.90 | GCGR (0.49) | GCGRGIPRMEN1KMT2AKDM4E | |
| SCHEMBL5585561 | 0.85 | GCGR (0.53) | GCGRGIPRMEN1KMT2AKDM4E | |
| SCHEMBL5585462 | 0.85 | GCGR (0.51) | GCGRGIPRMEN1KMT2AKDM4E | |
| SCHEMBL5585470 | 0.85 | GCGR (0.49) | GCGRGIPRPTGESALOX5MEN1 | |
| SCHEMBL5585661 | 0.84 | GCGR (0.43) | GCGRGIPRMEN1KMT2AKDM4E | |
| SCHEMBL1746621 | 0.84 | KMT2A (0.60) | MEN1KMT2AKDM4ERAB9APOLB | |
| SCHEMBL5585256 | 0.83 | GCGR (0.44) | GCGRGIPRMEN1KMT2AKDM4E | |
| SCHEMBL6001016 | 0.82 | GCGR (0.42) | GCGRGIPRMEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7163952-B2 | Azole compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2007-01-16 | — | — | US | disclosed |
| US-7163952-B2 | Azole compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2007-01-16 | — | — | US | disclosed |
| US-7163952-B2 | Azole compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2007-01-16 | — | — | US | disclosed |
| US-20050065196-A1 | Azole compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2005-03-24 | — | — | US | disclosed |
| EP-1452530-A1 | AZOLE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2004-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065196-A1 | Azole compound and medicinal use thereof | PTPN7, PTPN1, PTPN5 | GCGR 317/4885GIPR 195/4885PTGES 4468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.